Company intelligence / Profile preview
Cytoki Pharma
Søborg, Capital Region, Denmarkcytokipharma.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Other
01
Overview
Cytoki Pharma is a clinical-stage biotech company developing a new class of medicines based on IL‑22 biology. Their lead candidate, CK‑0045, is in Phase 2 trials and aims to address metabolic diseases such as obesity and type 2 diabetes by driving healthy weight loss and broader metabolic effects. The company’s approach leverages the unique properties of IL‑22 to target epithelial tissues involved in these conditions. Early data suggest differentiated efficacy compared to existing therapies like GLP‑1 agonists, with potential for fewer gastrointestinal side effects[1][4].
- Therapeutic areas
- GastroenterologyEndocrinologyDermatology
- Modalities
- Protein therapeuticsLong-acting IL‑22 analogues[1][4]
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Cytoki Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cytoki Pharma.